Science at Our Core. Patients in Our Hearts.
Palo Alto, CA
Joined August 2016
- Tweets173
- Following55
- Followers241
- Likes41
Phase 1 results for IO-202, our anti-LILRB4 antibody, are now in @Bloodneoplasia. The data show promising activity in #CMML and #AML, offering new hope for patients with limited treatment options.
Read more: immune-onc.com/pr-posts/immu…
The first patient has been dosed in our global Ph 1b/2 trial evaluating IO-108 for 1st-line treatment of HCC in clinical collaboration with Roche!
A major step forward in our mission to advance cancer care. Learn more: bit.ly/4ihX9Op
We’re back from #ASH2024 and inspired by the energy and engagement around our oral presentation on IO-202 for #CMML. This is a key step toward new hope for people with this rare blood cancer.
Thank you to everyone who joined us.
ICYMI: bit.ly/3OIEI8V
Today, we are proud to present groundbreaking new Phase 1b data on IO-202 for #CMML at #ASH2024!
✔️ CR: 50% | ORR: 66.7%
✔️ High LILRB4 expression: CR: 83%; ORR: 100%
✔️ 40% bridged to transplant
✔️ Additional clinical benefits
Learn more: bit.ly/3OIEI8V
@ImmuneOnc will present important updates on its Phase 1b data on IO-202 for CMML. Don’t miss the oral presentation at #ASH2024 on Monday!
We’re proud to see @ImmuneOnc's IO-102 Ph 1 #CMML study featured in @LLSusa's announcement highlighting new data showing progress for hard-to-treat blood cancers. Looking forward to sharing more updates on the study at #ASH2024. bit.ly/3Oqvvly
Our Ph 1 data on IO-108 was published in @jitcancer !
· Durable responses in advanced solid tumors
· Promising monotherapy & combo results with pembrolizumab
· Potential to overcome resistance to checkpoint inhibitors
Read the full press release: bit.ly/4fu6e5N
We're thrilled to announce that Immune-Onc will present new IO-202 data for chronic myelomonocytic leukemia (CMML) at #ASH24! Join us to learn about the potential of our anti-LILRB4 antibody in addressing CMML, an underserved cancer with limited treatments bit.ly/40sNUW4
New from @ImmuneOnc at #EHA2024! Today, we will present additional positive interim Ph 1b expansion data for IO-202 in #CMML patients. The study shows early and sustained complete remissions among patients, regardless of their prognosis or mutation status. bit.ly/3Rs1SC7
#News: We look forward to presenting interim clinical data from our Phase 1b trial of IO-202 for the treatment of chronic myelomonocytic leukemia (#CMML) at the upcoming #EHA2024 Congress. View the press release for details: bit.ly/4bjpnoQ
Exciting News! The @SFBusinessTimes recognized our Orphan Drug Designation for IO-202 for #CMML as a recent breakthrough by women-led life sciences companies in the Bay Area. Read more here: bizjournals.com/sanfrancisco…
Great news! The FDA has granted IO-202 Orphan Drug Designation for the treatment of chronic myelomonocytic leukemia (CMML). Our Ph 1 study of IO-202 in combination with azacitidine is also currently enrolling newly diagnosed CMML patients. Read more here: bit.ly/48pyWQT
Excited to share a collaboration with @Roche evaluating IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) for the 1st line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma bit.ly/3I42pFk
Next week at the 3rd Tumor Myeloid-Targeted Therapies Summit in Boston, our very own Dr. Luke Chung will present encouraging Ph 1 data for IO-108, our first-in-class antibody targeting LILRB2 (ILT4). We hope to see you there (Wed., 7/19 - 1:30 PM)! bit.ly/3rhgQka
#Breaking: Our team and investigators will share the first clinical data on IO-202 (anti-LILRB4), our first-in-class #myeloid #checkpointinhibitor for the treatment of #AML and #CMML at the #EHA2023 congress in Frankfurt. Learn more: immune-onc.com/pr-posts/immu…
Next Tue., May 23, our CEO @charlene_liao and CFO Chris Whitmore look forward to meeting with investors 1:1 at the 2023 Wells Fargo Virtual Private Biotech Symposium to discuss how our platform of #myeloid #checkpointinhibitors is reigniting the field of #immunotherapy. #biotech
Why are we so excited about #immunotherapy? Because we’re playing a big role in its evolution. This week at #PEGS23 our CEO, @charlene_liao discussed our scientific approach and robust pipeline targeting myeloid checkpoints. Learn more at Immune-Onc.com
We are presenting clinical data for IO-202 for the first time at #EHA2023 next month! IO-202 is our first-in-class #myeloid #checkpointinhibitor targeting LILRB4 (aka ILT3) for the treatment of #AML and #CMML. Read below for info to attend the presentation ⬇️
#DYK that myeloid checkpoints could be game-changing targets for the field of #cancerimmunotherapy? Join our CEO @charlene_liao's presentation at the @CHI_Healthtech's 2nd Annual “Emerging Targets for Oncology and Beyond” conference at #PEGS23 next week. See you there!
